Mod­er­na eyes $500M sec­ondary of­fer­ing on up­beat coro­n­avirus vac­cine up­date — al­most ready for the clin­ic

Among the army of biotechs that threw them­selves in­to the gold rush for 2019-nCoV vac­cines or ther­a­pies, Mod­er­na emerged as one of the most le­git­i­mate con­tenders ... a cru­cial com­plex for ...